Last updated: 2026-09-04 21:06:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Gilead Sciences Inc. (GILD) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $150.99, with a market capitalisation of $185.51B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $108.46 to $157.29. This page covers its latest market performance, valuation, price trends and company information.
$185.51B | |
$149.23 | |
$157.29 | |
$6.28 | |
$151.22 | |
3.20M | |
-- | |
-- | |
$157.29 | |
$108.46 | |
2.17% | |
-- |
Gilead Sciences Inc. (GILD) is trading at $150.98 in after-hours trading as of 2026-09-04 21:00:00, down 0.16% ($0.24) from the regular-session close of $151.22.
After-hours trading shows how investors are pricing GILD after the regular session closes. The current after-hours price is near the regular-session close, indicating cautious after-hours sentiment.
Over the past seven days, Gilead Sciences Inc. (GILD) moved from $144.23 to $150.99, representing a gain of 4.69% ($6.76).
The stock traded between $149.23 and $151.37 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 5.11 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 87.1%
GILD is currently trading at $150.99, placing it 87.1% of the way from its 52-week low of $108.46 to its 52-week high of $157.29. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 17000 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Gilead Sciences Inc. (GILD) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.